129 related articles for article (PubMed ID: 8080669)
1. Serum p53 auto-antibodies: incidence in familial breast cancer.
Green JA; Mudenda B; Jenkins J; Leinster SJ; Tarunina M; Green B; Robertson L
Eur J Cancer; 1994; 30A(5):580-4. PubMed ID: 8080669
[TBL] [Abstract][Full Text] [Related]
2. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer.
Angelopoulou K; Diamandis EP
Eur J Cancer; 1997 Jan; 33(1):115-21. PubMed ID: 9071910
[TBL] [Abstract][Full Text] [Related]
3. The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Mudenda B; Green JA; Green B; Jenkins JR; Robertson L; Tarunina M; Leinster SJ
Br J Cancer; 1994 Jun; 69(6):1115-9. PubMed ID: 8198980
[TBL] [Abstract][Full Text] [Related]
4. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
Regidor PA; Regidor M; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
[TBL] [Abstract][Full Text] [Related]
5. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.
Kulić A; Sirotković-Skerlev M; Jelisavac-Cosić S; Herceg D; Kovac Z; Vrbanec D
Med Oncol; 2010 Sep; 27(3):887-93. PubMed ID: 19763913
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
Balogh GA; Mailo DA; Corte MM; Roncoroni P; Nardi H; Vincent E; Martinez D; Cafasso ME; Frizza A; Ponce G; Vincent E; Barutta E; Lizarraga P; Lizarraga G; Monti C; Paolillo E; Vincent R; Quatroquio R; Grimi C; Maturi H; Aimale M; Spinsanti C; Montero H; Santiago J; Shulman L; Rivadulla M; Machiavelli M; Salum G; Cuevas MA; Picolini J; Gentili A; Gentili R; Mordoh J
Int J Oncol; 2006 Apr; 28(4):995-1002. PubMed ID: 16525651
[TBL] [Abstract][Full Text] [Related]
7. Absence of p53 autoantibodies in a significant proportion of breast cancer patients.
Vojtesek B; Kovarik J; Dolezalova H; Nenutil R; Havlis P; Brentani RR; Lane DP
Br J Cancer; 1995 Jun; 71(6):1253-6. PubMed ID: 7779720
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
9. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
10. Serum p53 antibodies in correlation to other biological parameters of breast cancer.
Sangrajrang S; Arpornwirat W; Cheirsilpa A; Thisuphakorn P; Kalalak A; Sornprom A; Soussi T
Cancer Detect Prev; 2003; 27(3):182-6. PubMed ID: 12787724
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a panel of tumor-associated antigens in breast cancer.
Pagaza-Straffon C; Marchat LA; Herrera L; Díaz-Chávez J; Avante MG; Rodríguez YP; Arreola MC; López-Camarillo C
Cancer Biomark; 2020; 27(2):207-211. PubMed ID: 31839604
[TBL] [Abstract][Full Text] [Related]
12. P53 autoantibodies in 1006 patients followed up for breast cancer.
Metcalfe S; Wheeler TK; Picken S; Negus S; Jo Milner A
Breast Cancer Res; 2000; 2(6):438-43. PubMed ID: 11056691
[TBL] [Abstract][Full Text] [Related]
13. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer.
Coomber D; Hawkins NJ; Clark M; Meagher A; Ward RL
J Cancer Res Clin Oncol; 1996; 122(12):757-62. PubMed ID: 8954174
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Lu H; Ladd J; Feng Z; Wu M; Goodell V; Pitteri SJ; Li CI; Prentice R; Hanash SM; Disis ML
Cancer Prev Res (Phila); 2012 Aug; 5(8):1036-43. PubMed ID: 22715141
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
16. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
[TBL] [Abstract][Full Text] [Related]
17. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression.
Volkmann M; Sinn HP; Gaugel D; Frey M; Hajjar Y; Ludwig J; Hänsel S; Bastert G; Wallwiener D; Fiehn W; Zentgraf H; Huober J
Oncology; 2002; 63(3):297-305. PubMed ID: 12381910
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.
Angelopoulou K; Yu H; Bharaj B; Giai M; Diamandis EP
Clin Biochem; 2000 Feb; 33(1):53-62. PubMed ID: 10693987
[TBL] [Abstract][Full Text] [Related]
19. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
20. The significance of p53 autoantibodies in the serum of patients with breast cancer.
Willsher PC; Pinder SE; Robertson L; Nicholson RI; Ellis IO; Bell JA; Blamey RW; Green JA; Robertson JF
Anticancer Res; 1996; 16(2):927-30. PubMed ID: 8687153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
